Abstract
Pembrolizumab, one of many novel immune checkpoint inhibitors (ICPi), is a monoclonal antibody that enhances immunity against cancer cells. Extensive ......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
